Merck Total Long-Term Assets 2010-2024 | MRK

Merck total long-term assets from 2010 to 2024. Total long-term assets can be defined as the sum of all assets classified as non-current
  • Merck total long-term assets for the quarter ending September 30, 2024 were $77.171B, a 3.21% increase year-over-year.
  • Merck total long-term assets for 2023 were $74.507B, a 1.46% increase from 2022.
  • Merck total long-term assets for 2022 were $73.438B, a 2.64% decline from 2021.
  • Merck total long-term assets for 2021 were $75.428B, a 18.18% increase from 2020.
Merck Annual Total Long-Term Assets
(Millions of US $)
2023 $74,507
2022 $73,438
2021 $75,428
2020 $63,824
2019 $56,914
2018 $56,762
2017 $63,106
2016 $64,763
2015 $71,926
2014 $65,562
2013 $69,960
2012 $71,275
2011 $71,947
2010 $76,717
2009 $83,882
Merck Quarterly Total Long-Term Assets
(Millions of US $)
2024-09-30 $77,171
2024-06-30 $74,425
2024-03-31 $74,404
2023-12-31 $74,507
2023-09-30 $74,773
2023-06-30 $74,492
2023-03-31 $74,394
2022-12-31 $73,438
2022-09-30 $73,520
2022-06-30 $74,979
2022-03-31 $75,484
2021-12-31 $75,428
2021-09-30 $62,436
2021-06-30 $62,023
2021-03-31 $63,938
2020-12-31 $63,824
2020-09-30 $63,223
2020-06-30 $61,272
2020-03-31 $58,739
2019-12-31 $56,914
2019-09-30 $57,189
2019-06-30 $59,667
2019-03-31 $57,003
2018-12-31 $56,762
2018-09-30 $58,294
2018-06-30 $60,976
2018-03-31 $61,956
2017-12-31 $63,106
2017-09-30 $63,757
2017-06-30 $64,637
2017-03-31 $65,031
2016-12-31 $64,763
2016-09-30 $68,895
2016-06-30 $68,549
2016-03-31 $69,983
2015-12-31 $71,926
2015-09-30 $72,665
2015-06-30 $74,263
2015-03-31 $75,418
2014-12-31 $65,562
2014-09-30 $67,085
2014-06-30 $64,273
2014-03-31 $67,220
2013-12-31 $69,960
2013-09-30 $68,654
2013-06-30 $69,881
2013-03-31 $70,956
2012-12-31 $71,275
2012-09-30 $70,072
2012-06-30 $69,886
2012-03-31 $71,165
2011-12-31 $71,947
2011-09-30 $72,425
2011-06-30 $73,827
2011-03-31 $74,841
2010-12-31 $76,717
2010-09-30 $80,084
2010-06-30 $79,917
2010-03-31 $83,349
2009-12-31 $83,882
2009-09-30 $19,071
2009-06-30 $20,173
2009-03-31 $20,359
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $244.211B $60.115B
Merck & Co. boasts more than six blockbuster drugs in its portfolio with PD-L1 inhibitor, Keytruda, approved for several types of cancer. Keytruda has played an instrumental role in driving Merck's steady revenue growth in the past few years. Well-known products in Merck's portfolio include Keytruda, Simponi , Januvia and Janumet, Bridion, Isentress, ProQuad, Gardasil, Pneumovax 23, RotaTeq and Belsomra. Merck made its biggest acquisition of Schering-Plough and sold off its Consumer Care business to Bayer. Other key acquisitions include Idenix Pharmaceuticals, Cubist Pharmaceuticals, Rigontec, ArQule and Acceleron Pharma. IMerck spun off products from its Women's Health unit, legacy drugs and biosimilar products into a new publicly traded company called Organon & Co.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $692.744B 71.75
Novo Nordisk (NVO) Denmark $460.555B 33.21
Johnson & Johnson (JNJ) United States $368.366B 14.94
AbbVie (ABBV) United States $294.353B 15.49
Novartis AG (NVS) Switzerland $211.084B 14.03
AstraZeneca (AZN) United Kingdom $197.819B 16.83
Pfizer (PFE) United States $142.241B 9.73
Sanofi (SNY) $121.816B 11.03
Innoviva (INVA) United States $1.195B 9.94